Abstract 5089
Background
The variability of clinical response to immune checkpoint inhibitors in RCC patients makes necessary the discovery of predictive biomarkers for patient selection. Emerging evidence has revealed a multitude of silenced genes and deregulated signalling pathways. These findings point towards extensive microRNAs (miRNAs) regulation and imply epigenetic reprogramming as a key feature of RCC. The aim of this study was to analyze the peripheral lymphocyte miRNA expression profile in metastatic RCC patients undergoing nivolumab treatment, to identify a lymphocyte miRNA signature specifically expressed in patients with partial or complete response (RP; RC) >12 months.
Methods
miRNAs were isolated from peripheral lymphocytes of 18 mRCC patients treated with nivolumab as 2nd line. The blood samples were collected before starting treatment (T0) and after 4 weeks (T1). The expression profile of 377 miRNAs was analyzed, with a cut off of fold change >2 for up-regulated and <0.3 for down-regulated miRNAs. Patients were divided into 2 groups: i) patients with disease progression (PD) within 6 months of treatment (P1); ii) patients with durable response (SD, RP, RC) >12 months (P2).
Results
Microarray analysis showed several differentially expressed miRNAs in peripheral lymphocytes of P1 and P2, involved in RCC signaling pathways such as VHL-HIF, PI3K/Akt, PTEN and WNT-β-catenin. Surprisingly, patients with RC > 12 months showed a subset of 8 miRNAs (miR-24, miR-22, miR-99a, miR-708, miR-339, miR-335, miR-214, miR-194) specifically induced by nivolumab treatment. These miRNAs are silenced or downregulated in RCC. This could explain the exceptional up-regulation in long-responder patients, evident already after 4 weeks of treatment.
Conclusions
Our study for the first time analyzed the miRNA expression profile in peripheral lymphocytes and showed the exceptional up-regulation of a specific subset of miRNA only in RCC patients with durable (<12 months) and complete response to nivolumab treatment. These findings could help to identify novel predictive biomarkers urgently needed to guide clinical decision-making in RCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Department of Surgical, Oncological and Oral Sciences, University of Palermo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract